357 filings
Page 6 of 18
8-K
ottxle
6 Oct 17
Entry into a Material Definitive Agreement
12:00am
8-K
mulktq
4 Oct 17
Results of Operations and Financial Condition
12:00am
8-K
8t5crlk12bh2h5
26 Sep 17
Entry into a Material Definitive Agreement
12:00am
8-K
b2of42zqrdfp
12 Sep 17
Unregistered Sales of Equity Securities
12:00am
8-K
5rl2ix
1 Sep 17
Immunogen Announces Agreements to Exchange
12:00am
8-K
2iq4kk4qxz8zj8
29 Aug 17
Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a
12:00am
8-K
8ejly
28 Jul 17
ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results
12:00am
8-K
b6gt8ew3s
16 Jun 17
Departure of Directors or Certain Officers
12:00am
8-K
2gpgr73d
30 May 17
ImmunoGen and Sanofi Amend License Agreements
12:00am
8-K
seyto6ghqmn 1s1snk
23 May 17
Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen
12:00am
8-K
r1m6rl lrbz9ssbqu
5 May 17
ImmunoGen Reports Recent Progress and First Quarter 2017 Operating Results
12:00am
8-K
gi2qbi2kr
5 Apr 17
Departure of Directors or Certain Officers
12:00am
8-K
sg99cue1e
17 Feb 17
Results of Operations and Financial Condition
12:00am
8-K
mg474g4qn6fq uej0q
23 Jan 17
ImmunoGen Announces Departure of Sandra Poole
12:00am
8-K
kw60gj3 tlr
12 Jan 17
Results of Operations and Financial Condition
12:00am
8-K
usru3u 4qe9pasnqfq9
4 Jan 17
Departure of Directors or Certain Officers
12:00am
8-K
dbs z8bid1qi89o6zs
13 Dec 16
Departure of Directors or Certain Officers
12:00am
8-K/A
heshdjnl
4 Nov 16
Cost Associated with Exit or Disposal Activities
12:00am
8-K
mchujx
28 Oct 16
ImmunoGen Reports Financial Results for Quarter Ended September 30 and Reviews Business Highlights
12:00am
8-K
qa67gt 0e
29 Sep 16
ImmunoGen Completes Strategic Review to Strengthen the Organization and Drive Long-Term Growth
12:00am